Atlas Trials

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Clinical trial NCT00975767 · TERMINATED

Trial details

NCT number
NCT00975767
Sponsor
Mirati Therapeutics Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Malignancies, Non-small Cell Lung Cancer
Start date
2009-08-01
Primary completion
2013-07-01
Enrollment
126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.